# Esomeprazole Plus Sucralfate for Post-ESD Ulcer Healing

> **NCT07312370** · PHASE4 · NOT_YET_RECRUITING · sponsor: **LanZhou University** · enrollment: 120 (estimated)

## Conditions studied

- Early Gastric Cancer
- Gastric Dysplasia
- Gastric Neoplasms
- Peptic Ulcer With Haemorrhage
- Gastric Ulcer

## Interventions

- **DRUG:** Esomeprazole (Intravenous)
- **DRUG:** Esomeprazole (Oral)
- **DRUG:** Sucralfate Suspension
- **PROCEDURE:** Gastric Endoscopic Submucosal Dissection (ESD)

## Key facts

- **NCT ID:** NCT07312370
- **Lead sponsor:** LanZhou University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-20
- **Primary completion:** 2026-12-20
- **Final completion:** 2026-12-30
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07312370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07312370, "Esomeprazole Plus Sucralfate for Post-ESD Ulcer Healing". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT07312370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*